The Sentinel


Wednesday, January 16, 2019

JITC Letter from the Editor - January 2019

pedro-romero_1__1_.jpgDear JITC Readers,

In the January edition of the JITC Digest, there are four noteworthy articles of which I would like to draw special attention. First, the article “Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication,” by Gijs G. Zom et al. reports novel murine data demonstrating the enhanced immunological potency of the novel TLR2-ligand, Amplivant (AV), as an adjuvant in cancer immunotherapy. Such results lay the foundation for further clinical testing of AV-synthetic long peptide (SLP) conjugates.

Next, the research article, “1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis,” by Yutao Yan et al. establishes a crucial immunosuppressive mechanism utilized in prostate cancer by which metabolites released by prostate cancer cells directly impair T cell immunity and anti-tumor functionality.

Furthermore, the article, “Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy,” by George Fromm et al. details the development and characterization of Agonist Redirected Checkpoint™ (ARC), a dual-sided Fc fusion protein platform for the linking of specific checkpoint and costimulatory pathways. Fromm’s group specifically reports on the anti-tumor response and potential therapeutic activity of the prototype ARC molecule, PD1-Fc-OX40L, for both human and mouse.

Finally, Larissa S. Carnevalli et al.’s article, “PI3K-alpha/delta inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity,” examines the immune response elicited by AZD8835, a dual PI3K-alpha/delta inhibitor, through preclinical syngeneic tumor models and determines how differential dosing of the inhibitor affects anti-tumor immunity through interactions with the tumor immune microenvironment.

With best regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

To view the entire January 2019 JITC Digest, please click here

No comments:

Post a Comment